Alexandru Eniu

TL;DR: The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed.

TL;DR: The burden of breast and cervical cancer is described, with an emphasis on global and regional trends in incidence, mortality, and survival, and the consequences, especially in socioeconomically disadvantaged women in different settings.

TL;DR: Focus groups addressed specific issues in breast pathology, radiation therapy, and management of locally advanced disease and indicated that cancer prevention through health behavior modification could influence breast cancer incidence in LMCs.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: The NeoALTTO trial showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not, and the association between pathological complete responded and overall survival was assessed.